KRAS-mutations are one of the most common genetic events in lung ADC and constitutively activate effectors downstream of EGFR, thus they can potentially cause TKI-resistance and be a negative predictive biomarker for response to EGFR-TKIs in NSCLC [37]. This evidence concerns the gene KRAS and medical procedure.